J&J Immunology President On Remicade, Inflectra And The Art Of Contract Negotiations
Executive Summary
Janssen Biotech's Immunology President Scott White defended the company's Remicade contracting strategy in an interview and outlined why J&J believes it has been unfairly targeted in an anti-competitive lawsuit filed by rival Pfizer.
You may also be interested in...
IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.
Pfizer’s Big Bet On Arena Pays Off With First Phase III Win For Etrasimod In UC
The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.
Charting The Slow-Growing Psoriatic Arthritis Market
Market Snapshot: Despite the availability of anti-TNF biosimilars, the global market for drugs for psoriatic arthritis will grow to $4.1bn in 2025 due to the entry of new branded drugs at high prices in the US, according to a new Datamonitor Healthcare forecast report.